Abstract
Purpose
Health related quality of life (HRQoL) was characterized among patients with neuroendocrine tumor (NET) and compared with the general Norwegian population.
Methods
A cross sectional, comparative design was chosen, and the samples comprised 196 NET patients and 5,258 individuals from the general Norwegian population.
We used Chi-square cross tab calculations to evaluate sociodemographic characteristics, T-tests for independent samples and Analysis of Variance (ANOVA) in order to compare HRQoL (SF-36) scores across a range of background variables. Furthermore, T-tests were used to analyze differences in HRQoL scores between the samples.
Results
NET patients demonstrated significantly lower on all HRQoL subscales when compared with the general population with the lowest values on general health, physical limitation and vitality. Individuals above 70 years reported lower scores on physical functioning and physical limitations compared with those who were younger. Individuals with higher levels of education reported increased physical functioning compared with those with less education and full-time or part-time workers described higher physical functioning and less physical limitations compared with those who were retired.
Conclusions
All SF-36 HRQoL scores were significantly lower among the NET patients when compared with the general population. Assistance from health personnel to NET patients should focus on those domains.
Similar content being viewed by others
Abbreviations
- HRQoL:
-
Health related quality of life
- NET:
-
Neuroendocrine tumor
- SF-36:
-
The short form 36 questionnaire
- GF:
-
General health
- PF:
-
Physical functioning
- MH:
-
Mental health
- RP:
-
Role-limitations-physical
- RE:
-
Role-limitations-emotional
- VT:
-
Vitality
- SF:
-
Social functioning
- BP:
-
Bodily Pain
- ANOVA:
-
Analysis of variance
- ES:
-
Effect size
References
Oberg, K. (2003). Diagnosis and treatment of carcinoid tumors. Expert Review of Anticancer Therapy, 3(6), 863–877. doi:10.1586/14737140.3.6.863. Review 134 refs.
Oberg, K. (1994). Endocrine tumors of the gastrointestinal tract: Systemic treatment. Anti-Cancer Drugs, 5(5), 503–519. doi:10.1097/00001813-199410000-00001. Review 93 refs.
Knox, C. D., Feurer, I. D., Wise, P. E., Lamps, L. W., Kelly, W. J., Chari, R. S., et al. (2004). Survival and functional quality of life after resection for hepatic carcinoid metastasis. Journal of Gastrointestinal Surgery, 8(6), 653–659. doi:10.1016/j.gassur.2004.04.003.
Norheim, I., Oberg, K., Theodorsson-Norheim, E., Lindgren, P. G., Lundqvist, G., Magnusson, A., et al. (1987). Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Annals of Surgery, 206(2), 115–125.
Ware, J. E., Jr., Kosinski, M., & Keller, S. D. (1994). SF-36 Physical and mental health summary scales: A user’s manual (5th ed.). Boston, MA: Health Assessment Lab
Larsson, G., Von Essen, L., & Sjoden, P. O. (1998). Quality of life in patients with endocrine tumors of the gastrointestinal tract: Patient and staff perceptions. Cancer Nursing, 21(6), 411–420. doi:10.1097/00002820-199812000-00005.
Larsson, G., Widmark, P. V., Lampic, C., von Essen, L., & Sjoden, P. O. (1998). Cancer patient and staff ratings of the importance of caring behaviors and their relations to patient anxiety and depression. Journal of Advanced Nursing, 27(4), 855–864. doi:10.1046/j.1365-2648.1998.00583.x.
Ramage, J. K., & Davies, A. H. (2003). Measurement of quality of life in carcinoid/neuroendocrine tumours. Endocrine-Related Cancer, 10(4), 483–486. doi:10.1677/erc.0.0100483.
Larsson, G., Sjoden, P. O., Oberg, K., Eriksson, B., & Von Essen, L. (2001). Health-related quality of life, anxiety and depression in patients with midgut carcinoid tumours. Acta Oncologica, 40(7), 825–831. doi:10.1080/02841860152703445.
Frojd, C., Larsson, G., Lampic, C., & von Essen, L. (2007). Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study. Health and Quality of Life Outcomes, 5, 18. doi:10.1186/1477-7525-5-18.
Berglund, G., Liden, A., Hansson, M. G., Oberg, K., Sjoden, P. O., & Nordin, K. (2003). Quality of life in patients with multiple endocrine neoplasia type 1 (MEN 1). Familial Cancer, 2(1), 27–33. doi:10.1023/A:1023252107120. Erratum appears in Fam Cancer. 2003;2(2):151.
Larsson, G., Sjoden, P. O., Oberg, K., & von Essen, L. (1999). Importance-satisfaction discrepancies are associated with health-related quality of life in five-year survivors of endocrine gastrointestinal tumours. Annals of Oncology, 10(11), 1321–1327. doi:10.1023/A:1008360718646.
Hjermstad, M. J., Fayers, P. M., Bjordal, K., & Kaasa, S. (1998). Using reference data on quality of life—the importance of adjusting for age and gender, exemplified by the EORTC QLQ-C30 (+3). European Journal of Cancer, 34(9), 1381–1389. doi:10.1016/S0959-8049(98)00136-1.
McHorney, C. A., Ware, J. E., Jr., Lu, J. F., & Sherbourne, C. D. (1994). The MOS 36-item short-form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Medical Care, 32(1), 40–66. doi:10.1097/00005650-199401000-00004.
Norwegian Social Sience data Services (NSD). (2003). SF-36 data from the General population (n = 5152). Norway, The Norwegian Social Science Data Services, The Norwegian Survey Archive (www.nsd-uib.no/english/2006).
Albert, S. M., Frank, L., Kleinman, L., Leidy, N. K., Legro, M., Shikiar, R., et al. (1998). Defining and measuring quality of life in medicine. JAMA. Journal of the American Medical Association, 279(6), 429–431. doi:10.1001/jama.279.6.429.
Davies, A. H. G., Larsson, G., Ardill, J., Friend, E., Jones, L., Falconi, M., et al. (2006). Development of a disease-specific quality of life questionnaire module for patients with gastrointestinal neuroendocrine tumours. European Journal of Cancer, 42(4), 477–484. doi:10.1016/j.ejca.2005.10.025.
Ware, J. E., Jr., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30(6), 473–483. doi:10.1097/00005650-199206000-00002.
Loge, J. H., & Kaasa, S. (1998). Short form 36 (SF-36) health survey: Normative data from the general Norwegian population. Scandinavian Journal of Social Medicine, 26(4), 250–258.
Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). New York: Academic Press.
King, M. T. (1996). The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Quality of Life Research, 5(6), 555–567. doi:10.1007/BF00439229. Review 35 refs.
Mols, F., Aaronson, N. K., Vingerhoets, A. J., Coebergh, J. W., Vreugdenhil, G., Lybeert, M. L., et al. (2007). Quality of life among long-term non-Hodgkin lymphoma survivors: A population-based study. Cancer, 109(8), 1659–1667. doi:10.1002/cncr.22581.
Boini, S., Briancon, S., Guillemin, F., Galan, P., & Hercberg, S. (2004). Impact of cancer occurrence on health-related quality of life: A longitudinal pre-post assessment. Health and Quality of Life Outcomes, 2, 4. doi:10.1186/1477-7525-2-4.
Hammerlid, E., & Taft, C. (2001). Health-related quality of life in long-term head and neck cancer survivors: A comparison with general population norms. British Journal of Cancer, 84(2), 149–156. doi:10.1054/bjoc.2000.1576.
Saegrov, S., & Halding, A. G. (2004). What is it like living with the diagnosis of cancer? European Journal of Cancer Care, 13(2), 145–153. doi:10.1111/j.1365-2354.2004.00442.x.
Tan, L. G., Nan, L., Thumboo, J., Sundram, F., & Tan, L. K. (2007). Health-related quality of life in thyroid cancer survivors. The Laryngoscope, 117(3), 507–510. doi:10.1097/MLG.0b013e31802e3739.
Oberg, K., Astrup, L., Eriksson, B., Falkmer, S. E., Falkmer, U. G., Gustafsen, J., et al. (2004). Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types. Acta Oncologica, 43(7), 626–636. doi:10.1080/02841860410018584.
Oberg, K., Astrup, L., Eriksson, B., Falkmer, S. E., Falkmer, U. G., Gustafsen, J., et al. (2004). Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview. Acta Oncologica, 43(7), 617–625. doi:10.1080/02841860410018575.
Oberg, K., & Eriksson, B. (1989). Medical treatment of neuroendocrine gut and pancreatic tumors. Acta Oncologica, 28(3), 425–431. doi:10.3109/02841868909111217 (Review 32 refs).
Acknowledgments
The authors are grateful to research assistant MSc Kristian Holm for his assistance in data collection and scanning of questionnaires. We would also like to thank Dr. Holli DeVon for providing thorough feedback of the manuscript. The study was funded by grants from The National Competence Centre for Neuroendocrine Tumors in Norway.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Haugland, T., Vatn, M.H., Veenstra, M. et al. Health related quality of life in patients with neuroendocrine tumors compared with the general Norwegian population. Qual Life Res 18, 719–726 (2009). https://doi.org/10.1007/s11136-009-9487-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11136-009-9487-x